Navigation Links
Finding suggests novel ways to boost vaccination or natural defenses
Date:7/7/2008

Our bodies rely on the production of potent, or 'high affinity', antibodies to fight infection. The process is very complex, yet Sydney scientists have discovered that it hinges on a single molecule, a growth factor, without which it cannot function.

There is much we do not yet understand about our immune system. In simple terms, our bodies produce B cells, which make antibodies, and T cells, which help them. Ways in which these cells operate and interact with each other are still coming to light.

Roughly eight years ago, a new subset of T cells, T follicular helper (TFH) cells, was identified. This important class of T cells operates in specific environments termed 'germinal centres', specialised areas within lymph organs where B cells proliferate to form high affinity antibodies whenever we fight infection. TFH cells play a critical role in that they communicate with, and help activate, B cells.

The novel finding made by Dr Cecile King and PhD student Alexis Vogelzang, from the Garvan Institute of Medical Research in Sydney, was that the molecule interleukin 21 (IL-21) is a growth factor for TFH cells. A paper detailing this finding was published online today in the prestigious international journal Immunity.

A cytokine, or chemical messenger, IL-21 is already well known to immunologists. While its newly identified growth factor role is only one of several functions, that function is fundamental. Without IL-21, the all-important TFH cells could neither develop nor survive.

Dr Cecile King, head of the Mucosal Autoimmunity Group at Garvan, has been investigating the roles of IL-21 for several years. "We already knew that IL-21 was produced by TFH cells and that it was a major initiator of proliferation in B cells," she said. "We were surprised to find that TFH cells not only produce IL-21, they also absolutely need it to survive and they utilise it to function."

"We showed that if you take a mouse genetically deficient in IL-21 and immunise it, you don't get TFH cells and you don't get antibody production. Conversely, if you put IL-21 receptor sufficient, or normal, T cells into the same mouse, where of course the B cells remain abnormal, you recover the normal immune reaction."

"These specialised T cells are thought to be the ones that direct traffic. They are the only ones that can move into the B cell zone and initiate high affinity antibody production."

"Without IL-21, we probably wouldn't be completely immunodeficient, just severely compromised. In addition to the high affinity antibodies we're talking about, our bodies also produce a lot of low affinity antibodies for mopping up infection. That low level response happens around-the-clock and is one of our body's first lines of defence."

"You could say that IL-21 directs the most finely-tuned aspect of our immune response. The highly specialised weaponry developed on-the-spot to target aggressive invaders."

"This finding suggests novel ways to boost vaccination or natural defences."


'/>"/>

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Research Australia
Source:Eurekalert

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
3. New MRI finding sheds light on multiple sclerosis disease progressio
4. High and mighty: first common height gene identified by researchers behind obesity gene finding
5. Scientists, physicians present latest findings in personalized cancer treatment and prevention
6. Health psychologists discuss latest research findings
7. Incidental findings found when radiologists take a broader look at renal MRA
8. First significant genetic finding in severe PMS, or PMDD
9. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
10. The Organic Trade Association Hails Preliminary Research Findings Showing Nutritional Benefits of Organic Products
11. Key findings for all veterans seen in depression and suicide study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology: